COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,317 Articles (22,772 medRxiv, 8,545 bioRxiv)

Most recent first Previous |  Page 1923: Articles 19221-19230  | Next

SARS-CoV-2 RBD in vitro evolution follows contagious mutation spread, yet generates an able infection inhibitor
Zahradnik, J., Marciano, S., Shemesh, M., Zoler, E., Chiaravalli, J., Meyer, B., Dym, O., Elad, N., Schreiber, G.
10.1101/2021.01.06.425392 — Posted: 2021-01-06 Discussion: Onsite
Chitinase 3-like-1 is a Therapeutic Target That Mediates the Effects of Aging in COVID-19
Kamle, S., Ma, B., He, C. H., Akosman, B., Zhou, Y., Lee, C.-M., El-Deiry, W. S., Huntington, K., Liang, O., Machan, J. T., Kang, M.-J., Shin, H. J., Mizoguchi, E., Lee, C. G., Elias, J. A.
10.1101/2021.01.05.425478 — Posted: 2021-01-06
Protein scaffold-based multimerization of soluble ACE2 efficiently blocks SARS-CoV-2 infection in vitro
Kayabolen, A., Akcan, U., Ozturan, D., Sarayloo, E., Nurtop, E., Ozer, B., Sahin, G. N., Dogan, O., Lack, N., Kaya, M., Albayrak, C., Can, F., Solaroglu, I., Bagci-Onder, T.
10.1101/2021.01.04.425128 — Posted: 2021-01-06
RNA-protein interaction analysis of SARS-CoV-2 5'- and 3'-untranslated regions identifies an antiviral role of lysosome-associated membrane protein-2
Verma, R., Saha, S., Kumar, S., Mani, S., Maiti, T. K., Surjit, M.
10.1101/2021.01.05.425516 — Posted: 2021-01-06
COVID-19 virtual patient cohort reveals immune mechanisms driving disease outcomes
Jenner, A. L., Aogo, R. A., Alfonso, S., Crowe, V., Smith, A. P., Morel, P. A., Davis, C. L., Smith, A. M., Craig, M.
10.1101/2021.01.05.425420 — Posted: 2021-01-06
Human cell-dependent, directional, time-dependent changes in the mono- and oligonucleotide compositions of SARS-CoV-2 genomes
Iwasaki, Y., Abe, T., Ikemura, T.
10.1101/2021.01.05.425508 — Posted: 2021-01-06
Adaptive immune responses to SARS-CoV-2 in recovered severe COVID-19 patients
Olea, B., Vicent, E. A., Torres, I., Amat, P., Remigia, M. J., Gozalbo, R., Rodriguez, J., Buesa, J., Blasco, M. L., Redon, J., Signes, J., Navarro, D.
10.1101/2021.01.05.20249027 — Posted: 2021-01-06
Modelling Decay of Population Immunity With Proposed Second Dose Deferral Strategy
Jurgens, G. T.
10.1101/2021.01.05.21249293 — Posted: 2021-01-06 Discussion: Onsite
Ivermectin shows clinical benefits in mild to moderate Covid19 disease: A randomised controlled double blind dose response study in Lagos.
Babalola, O. E., Bode, C. O., Ajayi, A. A., Alakaloko, F. M., Akase, I. E., Otrofanowei, E., Salu, O. B., Adeyemo, W. L., Ademuyiwa, A. O., Omilabu, S. A.
10.1101/2021.01.05.21249131 — Posted: 2021-01-06 Discussion: Onsite
Impaired performance of SARS-CoV-2 antigen-detecting rapid tests at elevated temperatures
Haage, V. C., Ferreira de Oliveira-Filho, E., Moreira-Soto, A., Kühne, A., Fischer, C., Sacks, J., Corman, V. M., Müller, M. A., Drosten, C., Drexler, J. F.
10.1101/2021.01.06.21249314 — Posted: 2021-01-06

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).